Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:54:01 EST Tue 09 Dec 2025
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q5.0119.26·119.290.2119.29-1.90-1.61,509.2179,80424,987121.07  122.24  119.05128.70  88.57513:38:0308:3015 min RT 2¢

Recent Trades - Last 10 of 24987
Time ETExPriceChangeVolume
13:38:13Q119.27-1.9220
13:38:11Q119.2648-1.925210
13:38:10Q119.2654-1.92461
13:38:09Q119.27-1.92100
13:38:05Q119.2667-1.92332
13:38:03Q119.27-1.9217
13:38:01Q119.2769-1.91311
13:38:01Q119.27-1.9247
13:37:59Q119.29-1.90100
13:37:59Q119.27-1.9230

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-09 08:30U:GILDNews ReleaseGilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
2025-12-07 08:00U:GILDNews ReleaseYescarta(TM) Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
2025-12-06 14:00U:GILDNews ReleaseKite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma
2025-12-06 14:00U:GILDNews ReleaseKite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
2025-11-24 08:30U:GILDNews ReleaseGilead Foundation Commits Over $3 Million to Address Food Insecurity
2025-11-20 07:02U:GILDNews ReleaseAspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
2025-11-18 05:00U:GILDNews ReleaseGilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
2025-11-13 08:30U:GILDNews ReleaseGilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
2025-11-07 08:30U:GILDNews ReleaseGilead Provides Update on Phase 3 ASCENT-07 Study
2025-11-07 08:00U:GILDNews ReleaseGilead's Livdelzi(TM) Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
2025-11-04 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2025-11-03 09:10U:GILDNews ReleaseGilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
2025-10-31 08:00U:GILDNews ReleaseGilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo(TM) (Lenacapavir)
2025-10-30 16:02U:GILDNews ReleaseGilead Sciences Announces Third Quarter 2025 Financial Results
2025-10-23 08:00U:GILDNews ReleaseGilead to Showcase Interim Long-Term Efficacy Data for Livdelzi(TM) (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
2025-10-19 08:30U:GILDNews ReleaseGilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
2025-10-19 02:30U:GILDNews ReleaseTrodelvy(TM) Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
2025-10-15 03:30U:GILDNews ReleaseGilead Presents New HIV Research Data at EACS 2025 - Driving Scientific Innovation in Treatment and Prevention
2025-10-13 08:30U:GILDNews ReleaseGilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
2025-10-09 16:05U:GILDNews ReleaseGilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025